Background: Silicone sheets are widely used in the treatment of hypertrophic scars, although application around joints may cause limited adherence and reduced movement. To approach these problems, a topical silicone gel was developed that can be applied easily in a thin layer, and that is nonrestrictive and less apparent. The objective of this study was to investigate the effectiveness of topical silicone gel in promoting the maturation of burn scars. Methods: Forty-six scars on 23 patients were included in a randomized, placebocontrolled, within-subject comparative, double-blinded, clinical trial and followed for 1 year. The mean age of the scars at inclusion was 4 months. Effectiveness on scar quality was evaluated using the Patient and Observer Scar Assessment Scale and the DermaSpectrometer. Significance was tested using repeated measures analyses and Wilcoxon paired-sample signed rank tests. Results: Over all visits, the benefit on surface roughness was statistically significant (p ϭ 0.012). At individual time points, the surface of the topical silicone gel-treated scars showed significantly less roughness (p ϭ 0.014) at 3 months after start of the treatment, and the topical silicone gel-treated scars were significantly less itchy (p ϭ 0.018 and p ϭ 0.013, respectively) at 3 and 6 months. Conclusion: Topical silicone gel significantly improves the surface roughness of burn scars, and patients experience significantly less itching in the first half year after application. (Plast. Reconstr. Surg. 126: 524, 2010.) 
D
eep dermal injuries such as burns are frequently followed by scarring. After wound closure, a normal course of maturation follows, characterized by an increasing occurrence of redness, thickness, stiffness, pain, and itching, and a disturbance in pigmentation and surface roughness. Burn scars can be functionally hindering and aesthetically disfiguring and can cause a great amount of psychological distress to the patient and his or her environment. [1] [2] [3] There is limited evidence to support the effectiveness of treatments for prevention or reduction of scarring, and recommendations are mostly based on experience of practitioners and small-scale trials without long-term follow-up. 4, 5 Nevertheless, there is consensus on the use of intralesional corticosteroid injections, occlusive dressings, custom-made pressure garments, and silicone sheets. 6, 7 Since the introduction in the early 1980s, silicones have been widely used in the treatment of burn scars. 8 Although the debate on the exact mechanism of action is ongoing, the noninvasive character makes the use of silicones easily acceptable for the patient, even as prophylaxis to hypertrophic scarring. 9 Silicones do have their limitations, as frequently shown in literature. 10 -12 Compliance can be low on scars on visible areas and when located adjacent to joints because they tend to restrict movement and sheets sometimes do not stay adherent. On visible areas, the appearance can make them less popular for the patient to wear. In addition, hygienic precautions should be taken daily, especially in hot climates, including disinfection of both the product and the skin to avoid irritation or rash. 12 Recently, a topical silicone gel named Dermatix (Meda Pharma, Amstelveen, The Netherlands) was introduced to overcome these disadvantages. It can be applied easily and dries to form a thin, flexible coating that does not restrict movement. Another advantage is that cosmetics can be applied over the silicone layer to camouflage the scar. These aspects are thought to increase the comfort of the patients and are therefore expected to improve compliance with therapy. Several studies have shown that topical silicone gel has the potential to reduce linear scarring after surgical treatments, but its effectiveness on burn scars has not been investigated in a controlled trial. [13] [14] [15] [16] We conducted a randomized, double-blinded, within-subject comparative, placebo-controlled trial to investigate the effectiveness of topical silicone gel in the treatment of scars resulting from a burn injury. Our working hypothesis was that topical silicone gel will induce the scar maturation process after burns by demonstrating a statistically significant reduction of scar characteristics in comparison with a placebo cream in time.
PATIENTS AND METHODS

Study Design
From October of 2005 to October of 2007, 23 patients who had read and signed the informed consent form were included in this trial. Each patient contributed two scars (one for the topical silicone gel treatment and one for the placebo treatment), which resulted in the use of 46 scars in this trial. The patients were eligible if they were 18 years or older and had at least two comparable scars after burns with a stable epithelialized skin layer. The scars were comparable if they had similar characteristics at inclusion in terms of overall scar appearance, depth of the initial injury, and location. Furthermore, the patient and the treating doctor had to be able to make a clear distinction between the two scar areas.
Patients were excluded from participation if there was a language barrier, if they were sensitive to occlusive dressings or silicone-containing products, or if they had a condition that could affect the compliance of the treatment negatively. They visited the clinic after 1, 3 , 6, and 12 months after the inclusion date. During these visits, effectiveness was evaluated by measuring differences in scar characteristics between the two treatments. The study protocol was approved by our regional ethics committee.
Treatments
The patients were given two blinded and coded products to be applied two times per day on the two included scars. One tube held a placebo cream and the other tube held Dermatix (kindly provided by Meda Pharma BV). The locations were predetermined randomly by the patients without them knowing which treatment each scar was about to receive. They were instructed not to interchange between therapies during the treatment period of 3 to 7 months, depending on the opinion of the treating doctor.
The placebo cream was white, nontransparent, indifferent cream cremor cetomacrogol FNA. It contained cetostearyl-alcohol, cetiol, and sorbitol. It is known for its neutral effect and is therefore often used as a commercial base preparation for mixing active ingredients. Dermatix is a combination of silicone and polytetrafluoroethylene. It dries to form a thin, transparent, flexible, gas-permeable, water-impermeable silicone coating that adheres to the skin without obstructing movement.
Scar Evaluation
Primary scar quality parameters were obtained by a single observer using the subjective Patient and Observer Scar Assessment Scale, 17 and because redness was one of the main parameters that was expected to show a difference, the DermaSpectrometer (Cortex Technology, Hadsund, Denmark) 18, 19 was used to measure the erythema index objectively.
The Patient and Observer Scar Assessment Scale is a questionnaire that consists of two numeric scales: the Patient Scar Assessment Scale (patient scale), which is to be completed by the patient; and the Observer Scar Assessment Scale (observer scale), which needs to be filled out by the observer. On a 10-point scale, they give their opinion on the parameters color (differentiated into redness and pigmentation in the observer part), thickness, surface roughness, and pliability. A low score Volume 126, Number 2 • Topical Silicone Gel for Burn Scars means a better scar quality: a 1 is scored if a scar characteristic is comparable to normal skin and a score of 10 reflects the worst imaginable scar. In addition, both the observer and the patient give their general impression on the quality of the scar with the item overall opinion. This item is not included in the total score or average of the Patient and Observer Scar Assessment Scale because it is not an individual scar characteristic but merely a summary of different aspects of the scar. In this trial, the scale provided an overall scar quality score by adding up the individual items and dividing it by the number of questions. Also, individual scar parameters were evaluated. During the course of this trial, the Patient and Observer Scar Assessment Scale questionnaire was extended with the item surface area by van de Kar et al. 20 This item was specially introduced for analysis of linear scars and was not used in this trial.
The DermaSpectrometer is based on narrowband simple reflectance using an erythema index. It was proven reliable for the evaluation of vascularization of burn scars in a study performed by Draaijers et al. in 2004. Each day, before the measurement took place, the tool was calibrated with a standard white-and-black plate. Because the comparative scars on the patient were sometimes located differently, season-related influences of sun exposure on the erythema score were eliminated by measuring a comparable location of unaffected skin.
Statistical Analyses
In this trial, we used repeated measures analyses for testing for differences in the development of the individual Patient and Observer Scar Assessment Scale scores over time between scars treated with silicone gel and the placebo cream. Repeated measures analyses are an extension of linear regression and analysis of variance for situations in which data are correlated. Normality was tested using the Kolmogorov-Smirnov test. As intraindividual Patient and Observer Scar Assessment Scale scores obtained at different times are generally more similar to one another than those for interindividual scars, statistical analyses for comparing these scores need to take into account the correlation between scores obtained on the same subject. A separate linear mixed model with time, treatment, and their interaction as withinsubject factors was fitted for each of the items on the Patient and Observer Scar Assessment Scale observer and patient scales. A compound symmetric correlation structure was used to model the withinsubject correlation. To account for pretreatment within-subject differences between scars, measurements obtained at baseline were introduced in the model by means of a covariate.
To test for treatment effects on the individual Patient and Observer Scar Assessment Scale scores at different times after the start of treatment, the Wilcoxon paired-sample signed rank test was used. This nonparametric test was preferred over the standard paired t test because a normality assumption was not valid for some Patient and Observer Scar Assessment Scale scores and times. The Patient and Observer Scar Assessment Scale scores obtained 1, 3, 6, and 12 months after the start of treatment were first corrected for baseline differences by subtracting the pretreatment scores. A similar statistical analysis was performed for the relative erythema measurements (scar area compared with control area) obtained with the DermaSpectrometer. All statistical analyses were conducted using SPSS version 15.0 (SPSS, Inc., Chicago, Ill.).
RESULTS
The mean age of the 23 patients was 38 years (range, 18 to 69 years); 13 were men and 10 were women. Their scars had a mean age of 123 postburn days (range, 36 to 338 postburn days) at the time of inclusion. The anatomical localizations of the scars are listed in Table 1 . Nineteen patients were available at the first-month follow-up visit, 18 at the 3-and 6-month follow-up visits, and 16 at the final follow-up visit after 1 year. The reasons for this loss to follow-up were failure to respond (n ϭ 4) and withdrawal by the patient because of lack of motivation (n ϭ 3). Both treatments were used for a mean time of 263 days (range, 195 to 347 days) and no side effects of the silicone gel or the placebo cream were reported. Self-reported compliance was not different for either product although, overall, patients did find the placebo more comfortable to apply and wear. Typical examples of two comparable scars on one patient at inclusion and at the 12-months follow-up are shown in Figure 1 . Figure 2 shows the average scores of the Patient and Observer Scar Assessment Scale items Plastic and Reconstructive Surgery • August 2010 scored by observer and patients. In general, the subject-specific profiles for these average scores show a large subject-to-subject variability for both treatments. The profiles for the overall means of these average scores are also plotted in Figure 2 . On average, observers rate scars treated with topical silicone gel slightly better than scars treated with the placebo cream. However, the repeated measures analysis did not show a significant treatment effect (p ϭ 0.154). The patients rated the scars treated with topical silicone gel and the placebo cream almost equally. Overall mean Patient and Observer Scar Assessment Scale scores for the different items on the observer and patient scales are plotted in Figures 3 and 4 , respectively. Although Patient and Observer Scar Assessment Scale scores for scars treated with topical silicone gel decreased a little faster on most scales, the repeated measures analyses only showed a significant treatment effect on the observer's score relief (p ϭ 0.012), with the topical silicone gel treatment leading to a lower score on this scale on all time points considered in the study. At 3 months after the start of the treatment, the observers rated the relief of the topical silicone gel-treated scars significantly better than the scars treated with the placebo cream (p ϭ 0.014, one-sided Wilcoxon signed rank test). After the third month, the difference in scores reduced slightly, which resulted in the treatment effect no longer being significant. In addition, a repeated measures analysis showed a nearly significant effect of treatment for the observer score for general impression (p ϭ 0.052). Similar to the observer's score relief, the topical silicone gel treatment led to lower general impression scores at all time points, with the difference being maximized at 3 months after the start of the treatment (p ϭ 0.029, one-sided Wilcoxon signed rank test).
Patient and Observer Scar Assessment Scale
In the repeated measures analyses, none of the patients' scores showed a significant treatment effect. However, when comparisons were made per time point, patients experienced less itching for the scars treated with topical silicone gel compared with the scars treated with the placebo cream at 3 and 6 months after the start of the treatment (p ϭ 0.018 and p ϭ 0.013, respectively, one-sided Wilcoxon signed rank test). No other significant treatment effects were found for the patient's scores.
DermaSpectrometer
The profiles for the overall mean of the relative erythema scores for the scars treated with topical silicone gel and the placebo cream are plotted in Figure 5 . Lower mean scores are found for the scars treated with topical silicone gel at all time points. However, the repeated measures analysis did not show a significant treatment result for the relative erythema scores (p ϭ 0.151). The relative erythema scores did not differ significantly between treatments when measurements made at different time points were considered separately.
DISCUSSION
In this study, we demonstrated that an application of topical silicone gel two times per day promoted the maturation of burn scars in most cases and significantly improved the surface roughness of the scars. It also significantly reduced itching in the first 3 to 6 months after application, when patients usually complain the most about this problem after burns. 21 These findings support the common notion that silicones have a signifi- Volume 126, Number 2 • Topical Silicone Gel for Burn Scars cant effect on burn scar maturation, especially considering the fact that this trial used a relatively small sample size.
However, our results are less outspoken in showing the beneficial effect of topical silicone gel compared with previous studies, performed on surgical scars. Chan et al. conducted a prospective, randomized, double-blind, within-subject comparative trial and included 50 patients who underwent a median sternotomy. 13 The participants were followed for 3 months, and the Vancouver Scar Scale was used to assess the effectiveness of the treatment. In all the scar parameters assessed, the differences were statistically significantly better in the topical silicone gel group compared with the placebo treatment.
Signorini and Clementoni investigated 160 patients with surgical scars and compared a treatment with topical silicone gel with no treatment. They used their own classification of scars according to morphologic features without mentioning the reliability of this classification. Scar quality was significantly better in the topical silicone gel group shown by a lower incidence of hypertrophic scars. Final evaluation of the scars was performed at 6 months after the operation. 14 Chernoff et al. 15 conducted a prospective, within-subject comparison trial of 30 patients (10 with topical silicone gel) with bilateral scars resulting from laser exfoliation. The evaluation included the use of a digital imaging program (optical profilometry), histologic punch biopsies, and linear analogue scar scores. After the first 3 months of application, they found that scars treated with silicone gel were statistically significantly less elevated, less red, and associated with fewer symptoms compared with untreated scars.
Clearly, these studies vary in study population and used different evaluation tools. Moreover, burn scars are very variable, making the results of these studies difficult to translate into burn scar treatment.
Recently, Karagoz et al. did compare topical silicone gel (Scarfade; Hanson Medical, Inc., Kingston, Wash.), silicone sheets (EpiDerm; MatTek Corp., Ashland, Mass.), and an onion extract (Contractubex; Merz Pharma, Frankfurt, Germany) on burn Volume 126, Number 2 • Topical Silicone Gel for Burn Scars scars. 22 Although a statistically significant benefit of topical silicone gel and silicone sheets was found compared with the onion extract, it was not clear what could be attributed to topical silicone gel because no placebo treatment was used and no intrapatient comparison was performed.
In general, it is difficult to demonstrate effectiveness of scar maturation-promoting agents/ regimens, because validated measurement tools have only become available relatively recently. 17, 19 A Cochrane review conducted by O'Brien and Pandit in 2009 on silicon gel sheeting for treatment of hypertrophic scars stated that there was inconsistency in instruments of measurement. 23 Similarly, their general conclusion was that trials in this area were of poor quality and highly susceptible to bias. Therefore, it is difficult to compare effectiveness of topical silicone gel to that of silicone sheets based on presently available data.
It is known that scar development is influenced by many factors, such as depth of the wound, injury type, skin type, and inflammatory reaction. Therefore, each patient has his or her own susceptibility to scar formation. By intraindividual comparison, we were able to eliminate most selection and assessment biases and confounders and create the optimal control group in this trial. We did experience that the patients had difficulties in distinguishing between the two scars. This might explain why the differences in scar quality scored by the observer were less apparent in the patient scores.
We used validated evaluation tools to asses the effectiveness of the treatment. The authors preferred the Patient and Observer Scar Assessment Scale over the Vancouver Scar Scale 24, 25 because it involves a wider range of scar characteristics, uses a 10-point scale instead of a variety-point scale, and combines the clinical interpretation of the treating doctor with the opinion of the patient.
Nevertheless, this trial was limited in some ways and some problems were encountered. The included scars were preferably comparable in terms of location and depth, but these criteria could not always be obtained. Clothing might have mechanically damaged the silicone layer because of friction, as earlier suggested in the literature, 14 and this could have reduced the treatment effect. Clothing could also have created an additional pressure therapy, which is known to have a positive effect on scar quality during maturation. 26 In the preparation of this trial, we found it very difficult to find a placebo treatment that had the same appearance as topical silicone gel but not the same consistency, because this consistency could very well be the working mechanism of silicone treatments. This is why our placebo treatment had a different appearance and consistency that might have affected the patient's and observer's blinding in this trial.
It might also be argued that the age of the scar is crucial for the effectiveness of silicone therapy and that our study population had relatively old scars (293) days. For this reason, we performed a post hoc analysis of a subgroup with young scars (Ͻ100 postburn days) but found similar outcomes (data not shown).
CONCLUSIONS
We conclude that topical silicone gel is effective in reducing the surface roughness of burn scars and that it effectively reduces burn scar pruritus in the first half year of application. On most of the other scar characteristics, some positive effects were observed, but these benefits were not statistically significant. We did not compare this treatment with silicone sheets but, because of its practical benefits, topical silicone gel could be a reasonable alternative when silicone sheets are contraindicated or not preferred by the patient. Because our study population was relatively small, it would be advisable to study the effects of topical silicone gel on a larger scale. A comparative study with topical silicone gel, silicone sheets, and placebo would be an ideal comparison. Plastic and Reconstructive Surgery • August 2010
